Share |
 Article not rated yet 

Evidence based Pediatrics

Bronchodilators in bronchiolitis: should we reassess their selective use?


Ochoa Sangrador Ca, Gimeno Díaz de Atauri Áb

aServicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
bServicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.

Correspondence: C Ochoa. Email:

Reference of this article.:

Ochoa Sangrador C, Gimeno Díaz de Atauri Á. Broncodilatadores en bronquiolitis: ¿debemos replantearnos su uso selectivo?. Rev Pediatr Aten Primaria. 2021;23:317-20.

Published in Internet: 20/09/2021


Authors’ conclusions: compared to guidelines‐guided strategy, treating infants with viral bronchiolitis using the phenotypic‐guided bronchodilator therapy strategy is a more cost‐effective strategy, because it involves a lower probability of hospital admission at lower total treatment costs. Randomized controlled trials using biomarkers to stratify patients most likely to respond to bronchodilators are necessary.

Reviewers’ commentary: the available information does not seem sufficient to make changes to the current recommendations in acute bronchiolitis management. There is still need for a predictive model that allows to identify potential responders to bronchodilators, as well as a clinical trial with a sufficient sample size to estimate the effectiveness of the strategy of its selective use.

Keywords: Costs and cost analysis.. Bronchodilators. Bronchiolitis.



This article has no comments yet.

ISSN 2174-4106  Publicación Open Acess, incluida en DOAJ, sin cargo por publicación.

Privacy Policy | Web map | Copyright 2022 Lúa Ediciones 3.0 | Contact